Correct Jase.The "price sensitivity" of the announcement is...

First 69 Last

Share
Profile

Follow
fourdollars

1,065 Posts.

1074

11/03/21

11:42

Post #: 51685171
Share

Originally posted by Jase99: ↑

Whilst I'm very excited about the prospect of updated results from the HER-Vaxx trial, to avoid disappointment I think everyone needs to cool their jets.

This announcement IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR from 2019 has the same disclaimer: "The content of the presentations are embargoed until the start of the conference and will be made available online after the start of the meeting and on the Imugene website."

Yes, it's great exposure to give a presentation at AACR, but no, I doubt it's setup to coincide with further/final results of the HER-Vaxx ph2 trial. (Although we may receive updated results in time for them to be talked about at AACR21.)

It's also worth bearing in mind the presentation is during the Phase I Clinical Trials session and it looks like it's a poster session and one of 47 presentations going on over a 3 hour period.

Expand

Correct Jase.

The "price sensitivity" of the announcement is IMU's way of trying to keep impatient shareholders at bay. IMU will construe that the exposure gained by presenting at such a conference is material to IMU. Maybe. What the "price sensitivity" does not relate to is any clinical progress with the trial that hasn't already been announced.

The "embargo" is simply a commercial requirement of AACR. They don't want presenters showing presentations prior to the conference, as it would make it harder to sell tickets. The AACR requirements don't supersede the ASX's requirements for ongoing disclosure, so again, it does not relate to clinical trial progress.

IMO, only significant price sensitive announcement on the horizon is efficacy data relating to PD1-Vaxx.

IMU Price at posting: 10.5¢ Sentiment: None Disclosure: Held
11 Upvote

0 Great analysis

Reply